Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Kumar, Shaji; Giralt, Sergio; A. Stadtmauer, Edward; Luc Harousseau, Jean; Palumbo, Antonio; Bensinger, William; L. Comenzo, Raymond; Lentzsch, Suzanne; C. Munshi, Nikhil; Niesvizky, Rubén; F. San Miguel, Jesús; Ludwig, Heinz; Bergsagel, Leif; Bladé, Joan; Lonial, Sagar; C. Anderson, Kenneth; Tosi, Patrizia; Sonneveld, Pieter; Sezer, Orhan; H. Vesole, David; Cavo, Michèle; Einsele, Hermann; G. Richardson, Paul; G.M. Durie, Brian; Vincent Rajkumar, S.

doi:10.1182/blood-2009-04-205013

Public

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Published in Blood • Jun 27, 2009

Authors:

Shaji Kumar

Sergio Giralt

Edward A. Stadtmauer

Abstract

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeut...

Subject

Lenalidomide

Multiple myeloma

Thalidomide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!